CLL Risk Variants Differ Across Low-Count MBL and CLL Groups

Key Takeaways
- Among Mayo Clinic–screened adults and patients with CLL, inherited CLL susceptibility variants were associated with both LC-MBL detection and the CLL-versus-LC-MBL comparison.
- Variant associations differed significantly between comparisons, and two pointed in opposite directions.
- The weighted 41-variant CLL risk score was significantly associated with both group comparisons.
In a genetic case-control analysis published in Cancers, Mayo Clinic Biobank screening identified 8,322 adults negative for monoclonal B-cell lymphocytosis (MBL) and 1,601 with CLL-type LC-MBL. The Mayo Clinic CLL Clinical Database supplied 2,606 patients with CLL. These were separate groups, not individuals followed from LC-MBL to CLL.
Screened adults were at least 40 years old and had no prior hematologic cancer. Investigators used eight-color flow cytometry on stored samples and excluded high-count MBL and non-CLL-type clones. They assessed 41 established CLL susceptibility variants and a weighted polygenic risk score (PRS). The analyses compared LC-MBL with MBL-negative status and, separately, CLL with LC-MBL as an indirect proxy for progression.
Logistic models adjusted for age, sex, and genetic principal components. Nominal associations required p < 0.05. Investigators estimated a 95% confidence interval (CI) for each association; differences between comparisons required a Wald test, Benjamini–Hochberg false discovery rate (FDR) < 0.05, and nonoverlapping CIs.
Of the established variants, 22 of 41 were nominally associated with LC-MBL versus MBL-negative status, and 20 of 41 with CLL versus LC-MBL. Eight met the criteria for differing associations. rs888096, rs9880772, rs305065, and rs1036935 had larger associations in the CLL-versus-LC-MBL contrast; rs34004493 and rs142215530 had larger associations with LC-MBL. The other two pointed in opposite directions: rs6708784 was positively associated with LC-MBL but inversely associated with CLL versus LC-MBL, while rs391855 showed the reverse pattern.
For LC-MBL versus MBL-negative status, the weighted PRS had an adjusted odds ratio (OR) of 1.77 (95% CI 1.66–1.88; p = 3.7 × 10−68). This comparison assessed detectable clones among screened adults, not subsequent CLL.
For CLL versus LC-MBL, the weighted PRS had an adjusted OR of 1.45 (95% CI 1.35–1.56; p = 8.1 × 10−24). Scores rose across the MBL-negative, LC-MBL, and CLL groups, but this contrast compared different people rather than tracking changes within individuals.
The separate groups cannot show which screened individuals later developed CLL or establish absolute individual progression risk. The investigators warned that reusing the LC-MBL group across comparisons could make their Wald test anti-conservative. High-count MBL was outside the analysis, and the PRS was not validated to predict subsequent CLL in people with LC-MBL.
According to the authors, inherited variant associations differed across the LC-MBL and CLL comparisons, while the weighted PRS was associated with both. Prospective LC-MBL follow-up and independent replication are needed to determine whether inherited susceptibility predicts subsequent CLL.
Clinician Questions
How was CLL-type low-count MBL identified in the Mayo Clinic genetic comparisons?
In Mayo Clinic Biobank screening, LC-MBL had a CLL-type immunophenotype (CD5-positive, CD20-dim or CD20-positive). In the included LC-MBL group, clonal B cells accounted for less than 85% of all B cells; that proportion was not the absolute clonal-count threshold used to distinguish low-count from high-count MBL.
How was the exploratory 20-variant CLL risk score evaluated against low-count MBL?
Investigators selected the 20 variants nominally associated with CLL versus LC-MBL from the 41 assessed variants and evaluated the resulting CLL PRS in the same participants. They cautioned that selecting variants and estimating associations in the same sample could inflate the exploratory score’s estimates, which require external validation.
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.